Rheumatoid Arthritis eJournal Club
 

Series Overview

Available treatment options for patients with RA continue to evolve and have improved the outlook for these patients. Even so, RA remains a leading cause of disability and many patients respond poorly, do not respond, or lose response over time to RA therapies.

In this series, the current peer-reviewed literature will be used as a knowledge base from which findings will be translated for clinical application by expert faculty members, who will discuss individual patient case histories.

This Virtual Grand Rounds series will give RA clinicians an opportunity to hear expert opinion on the management of complicated RA patient case histories that encompass diverse treatment challenges. Participants will be able to query the Program Chairperson on each case upon completion of the activity.

Ask the Expert

Participants have the opportunity to present questions to the Activity Director, Leonard H. Calabrese, DO, about the presented case through the Ask the Expert portal. To access this feature, begin the activity and enter in questions at the bottom portion of the screen.

Activity Director

Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
RJ Fasenmyer Chair of Clinical Immunology
Department of Rheumatic
   and Immunologic Diseases
Cleveland, Ohio

 


Target Audience

This activity is directed to rheumatologists and primary care physicians who treat patients with RA.

Accreditation

These activities have been approved for AMA PRA Category 1 Credit™.

Objectives

On completion of this educational series, participants will be able to:

  • Compare and contrast biologic therapies with regard to clinical outcomes and adverse effects in patients with RA
  • Discuss treatment considerations for a patient with RA and a comorbid condition for whom a DMARD or biologic therapy is being considered
  • Explain to a colleague current evidence-based treatment using biologic therapies in RA
  • Recognize the broad implications of clinical studies over the past 10 years for clinical practice for patients with RA